Like n comment-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
1
Favorite

loilily
2021-06-18

Like n comment

Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy

The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about

Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment（1）

Top
Latest

YoshiTei
·2021-06-18
help reply thanks
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":166531221,"tweetId":"166531221","gmtCreate":1624016576963,"gmtModify":1703826623690,"author":{"id":3581678001514026,"idStr":"3581678001514026","authorId":3581678001514026,"authorIdStr":"3581678001514026","name":"loilily","avatar":"https://static.tigerbbs.com/04e96538ee5fd71e82d5184875a47272","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like n comment</p></body></html>","htmlText":"<html><head></head><body><p>Like n comment</p></body></html>","text":"Like n comment","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/166531221","repostId":1133025835,"repostType":4,"repost":{"id":"1133025835","pubTimestamp":1624015886,"share":"https://www.laohu8.com/m/news/1133025835?lang=&edition=full","pubTime":"2021-06-18 19:31","market":"us","language":"en","title":"Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133025835","media":"cnbc","summary":"The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about","content":"<div>\n<p>The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPiper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 19:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1133025835","content_text":"The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe Food and Drug Administration’s approval of Aduhelm has been controversial, with multiple members of an FDA advisory committeeresigning in protestover the decision. There are concerns about the effectiveness of the treatment.\nPiper Sandler analyst Christopher Raymond said in a note to clients on Friday that he shared some of those concerns but that Aduhelm would still be a winner for Biogen’s business. Raymond upgraded the stock to overweight from neutral.\n“Despite our misgivings regarding FDA’s handling of the Aduhelm approval, we find two new data points too positive to ignore, and thus believe the path of least resistance on this stock is decidedly higher,” the note said.\nThose positive data points include a survey that shows strong demand and expected uptake for the drug, despite concerns about its effectiveness, and an expectation that Medicare and Medicaid will not significantly limit the available patient base for reimbursement, Piper Sandler said.\n“Combining this with what we see as a low-probability but still completely free call option that Biogen wins on appeal with the Tecfidera IP case, we think the stock is likely to go higher in the near term,” the note said.\nThe firm hiked its price target to $450 from $384, representing upside of 17% from where the stock closed on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":479,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":4869710,"commentId":"4869710","gmtCreate":1624017866389,"gmtModify":1663229298666,"authorId":3582431165926620,"author":{"id":3582431165926620,"idStr":"3582431165926620","authorId":3582431165926620,"name":"YoshiTei","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":166531221,"objectIdStr":"166531221","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"help reply <u>thanks</u>","text":"help reply <u>thanks</u>","html":"help reply <u>thanks</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}